Cyclodextrin polymer compositions for use as drug carriers

A controlled release pharmaceutical composition comprising;

• a) cyclodextrin molecules selected from the group consisting of cyclodextrin derivatives, oxidized cyclodextrins, cyclodextrin dimers, cyclodextrin trimers, and cyclodextrin polymers complexed with;
• b) nucleic acid, wherein;
• c) said cyclodextrin molecules are covalently cross-linked through a biocleavable linkage to form a polymer that has entrapped the active agent and wherein the cross-linking provides the function of controlled release.

A controlled release pharmaceutical composition comprising;

• a) cyclodextrin molecules selected from the group consisting of cyclodextrin derivatives, oxidized cyclodextrins, cyclodextrin dimers, cyclodextrin trimers, and cyclodextrin polymers complexed with;
• b) toxin, wherein;
• c) said cyclodextrin molecules are covalently cross-linked through a biocleavable linkage to form a polymer that has entrapped the active agent and wherein the cross-linking provides the function of controlled release.

A pharmaceutical amylose composition comprising;

• a) amylose selected from the group consisting of amylose segments, amylose derivatives, oxidized amylose and amylose polymers complexed with;
• b) an active agent, wherein;
• c) said amylose is covalently cross-inked to form a polymer that has entrapped the active agent.

A biocleavable crosslinking agent comprising;

• a) a compound containing a biocleavable linkage selected from the group consisting of polypeptide linkages and hydrazone linkages wherein;
• b) said compound has terminal reactive coupling groups selected from the group consisting of N-succinimidyls, N-maleimidyls, p-nitrophenyl esters, iodoacetals, bromoacetals, oxiranes and imidoesters.

A method for producing a cyclodextrin pharmaceutical composition comprising combining cyclodextrin molecules selected from the group consisting of cyclodextrin derivatives, cyclodextrin dimers, cyclodextrin trimers, and cyclodextrin polymers with;

• a) guest molecules coupled to a surface to form an inclusion complex between the cyclodextrin molecules and the guest molecules on the surface, and;
• b) covalently cross-linking the cyclodextrin molecules to form a polymer.

A method for producing a cyclodextrin pharmaceutical composition using a solid support comprising coupling a first cyclodextrin molecule selected from the group consisting of cyclodextrin derivatives, cyclodextrin dimers, cyclodextrin trimers, and cyclodextrin polymers to a solid support through a cleavable coupling agent and;

• a) coupling in succession, additional cyclodextrin molecules to the first cyclodextrin molecule that is coupled to the solid support to form a polymer and;
• b) cleaving the first cyclodextrin molecule from the solid support.

A pharmaceutical catalytic agent composition comprising;

• a) cyclodextrin molecules selected from the group consisting of oxidized cyclodextrins, cyclodextrin dimers, cyclodextrin trimers, and cyclodextrin polymers coupled with;
• b) a catalytic group selected from the group consisting of carboxylates, imidazoles, histamines, hydroxyls, amines, amides, aldehydes, ketones, phosphates, sulfhydryls, halogens, amino acids, nucleic acids, chelators, and metals.